Revision History
Isomorphic Labs · 14 revisions
Sizes are character counts of the article source. The signed number is the change from the previous revision.
Recent edit summaries
Detailed summaries recorded by editors. Generic maintenance summaries are omitted here; every recorded revision remains below. Dates describe the edit, not necessarily the event it covers.
- Update: added an official video.
Version 14 · Nov 1, 2026, 08:02 AM
- Correction: removed an unsupported Genentech partnership and an unsourced $9-11B Series B valuation range, fixed dates (Novartis deal Jan 7 2024, first round Mar 31 2025, Jaderberg appointment Nov 26 2025), ownership and clinical-timeline statements; corrected the leadership table (Hassabis is chair, not CEO, of Google DeepMind since Aug 2026; Miles Congreve was CSO of Sosei Heptares), removed an unsupported 'first chief medical officer' claim and Exscientia as a current competitor (merged into Recursion in 2024); added Bloomberg-reported Oct 2026 funding talks at >=$40B, Hassabis's Aug 2026 role change, 2025 Companies House accounts, and new sources.
Version 12 · Oct 27, 2026, 07:22 AM
- Improve internal links (2026-10-13)
Version 11 · Oct 13, 2026, 10:03 AM
- Added autonomous molecular design workflow and biological data collaboration
Version 10 · Oct 7, 2026, 10:23 PM
- Correction: Companies House citation pointed to the wrong record (13207520 is unrelated GG-895-389 LIMITED); the real record is Isomorphic Labs Limited, company number 13223825, and that is the registered name (no previous names on file).
Version 9 · Aug 7, 2026, 05:40 PM